Pharmacological issues in the treatment of tuberculosis

Annals of the New York Academy of Sciences

Volumn 953, Issue , 2001, Pages 157-164

  Peloquin, Charles A ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Cycloserine; Dosing regimen; Pharmacology; Therapeutic drug monitoring; Toxicity; Tuberculosis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LEVOFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; PYRAZINOIC ACID; RIFAMPICIN;

AREA UNDER THE CURVE; CONFERENCE PAPER; DISEASE DURATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MINIMUM INHIBITORY CONCENTRATION; PREGNANCY; TERATOGENESIS; TUBERCULOSIS;

EID: 0035690086     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb11374.x     Document Type: Conference Paper

References (28)

1. Methodological issues in pharmacokinetic-pharmaco-dynamic modeling
2. Using therapeutic drug monitoring to dose the antimycobacterial drugs
3. Pharmacodynamics of fluoroquinolones
4. The pharmacodynamics of aminoglycosides
5. The pharmacodynamics of β-lactams
6. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
7. Antimycobacterial agents: Cycloserine
8. Antimycobacterial agents: Ethionamide
9. Antituberculosis drugs: Pharmacokinetics
10. The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine
11. Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis
12. Tuberculosis recurrence: Multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors
13. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibiotics
14. Why monitor serum levels of gentamicin?
15. A critical reevaluation of the "therapeutic range" of aminoglycosides
16. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?
17. Routine monitoring of serum vancomycin concentrations: The answer lies in the middle
18. Serum vancomycin concentrations: Reappraisal of their clinical value
19. Editorial: Monitoring serum vancomycin levels: Climbing the mountain because it is there?
20. Tuberculosis drug serum levels
21. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo
22. Malabsorption of antimycobacterial medications
23. Drug malabsorption and resistant tuberculosis in HIV-infected patients
24. Goal-oriented, model-based drug regimens: Setting individualized goals for each patient
25. Treatment of tuberculosis and tuberculosis infection in adults and children